Clinical trials: Lymphomas,
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma
- Trial name
- NCT04934774
- Testing
- CD7 CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Hodgkin Lymphoma, Peripheral T Cell Lymphoma
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got…
- Conditions
- Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03947255
- Testing
- brentuximab vedotin
- Where
- 19 sites in United States
- Volunteers
- 12 people
- Sponsor
- Seagen Inc.
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
This randomized phase III trial is studying total-body irradiation (TBI) and fludarabine phosphate to see how it works compared with TBI alone followed by donor stem cell transplant in treating patients with hematologic cancer.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00075478
- Testing
- Total-Body Irradiation, Fludarabine Phosphate, Mycophenolate Mofetil
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 87 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Non-Hodgkin-Lymphoma
Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation
A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and…
- Conditions
- Multiple Myeloma, Non-Hodgkin-Lymphoma, Hodgkin's Disease
- Trial name
- OCTET-CY (NCT01283776)
- Testing
- Cyclophosphamide
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- University of Cologne
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Mycosis Fungoides
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
This phase II trial studies how well low dose total skin electron beam radiation therapy and mechlorethamine hydrochloride gel work in treating patients with mycosis fungoides.
- Trial name
- NCT03288818
- Testing
- Mechlorethamine Hydrochloride Gel, Total Skin Electron Beam Radiation Therapy
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Diffuse Large B Cell Lymphoma
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy.
- Trial name
- NCT05290090
- Testing
- Rituximab, Lenalidomide, Zanubrutinib and RCHOP
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang Cancer Hospital
T-cell Lymphoma, T-cell Leukemia
CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma.
- Trial name
- NCT03829540
- Testing
- CD4CAR
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Huda Salman
Marginal Zone Lymphoma
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma.
- Trial name
- NCT06454968
- Testing
- Orelabrutinib, obinutuzumab, lenalidomide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
- Trial name
- NCT04496349
- Testing
- APG-115, APG-2575
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Ascentage Pharma Group Inc.
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
The CARDIOPROTECT Trial
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care…
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Trial name
- NCT07654426
- Testing
- Dexrazoxane, Doxorubicin, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Beth Israel Deaconess Medical Center
Mantle Cell Lymphoma
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.
- Trial name
- BUS48T (NCT01504776)
- Testing
- Panobinostat, Bortezomib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Anand Jillella
Mediastinal Lymphadenopathy, Lung Cancer
Mediastinal EBUS Cryobiopsy Study In Sweden
This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other.
- Conditions
- Mediastinal Lymphadenopathy, Lung Cancer, Sarcoidosis, Lymphoma
- Trial name
- MECRIS (NCT06347939)
- Testing
- Mediastinal lymph nodes cryobiopsies
- Where
- 2 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Skane
B-cell Lymphoma
Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
To evaluate the CR rate of B-NHL subjects who achieved PR at intermediate assessment after first-line chemotherapy treated with autologous stem cell transplantation + Anti-CD19 CAR T cells.
- Trial name
- NCT05755828
- Testing
- ASCT+CAR-T Cell Infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Neoplasms, Lymphomas
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Background: Belinostat is an experimental cancer treatment drug that works by helping to turn on genes that limit cell growth and survival of cancer cells. These genes are often switched off in tumors.
- Trial name
- NCT01273155
- Testing
- Belinostat
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Leukemia
HeartPhone Cancer Survivors Trial 2019
This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone.
- Conditions
- Breast Cancer, Leukemia, Lymphoma
- Trial name
- NCT03953326
- Testing
- HeartPhone app, Acetylcholine, Sodium Nitroprusside
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Penn State University
Cutaneous T-Cell Lymphoma
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.
- Trial name
- NCT00490776
- Testing
- Panobinostat
- Where
- 18 sites in United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Lymphoma
Trial Comparing Active Intervention At Diagnosis With Usual Care to Improve Psycho-social Care in AYAO
Adolescents and young adults (AYA) patients experience significant distress in specific areas at diagnosis. The investigators hypothesize that providing developmentally-appropriate AYA-specific psychosocial care, with an…
- Conditions
- Carcinoma, Lymphoma, Sarcoma, Cancer
- Trial name
- NCT03515174
- Testing
- Supportive Care Program, Usual Care
- Where
- Singapore
- Volunteers
- 70 people
- Sponsor
- National Cancer Centre, Singapore
Lymphoma, Non-Hodgkin
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Aggressive non-Hodgkin's lymphoma is difficult to handle once it relapses or becomes refractory to chemotherapy. Various second or third line chemotherapies, which are called salvage chemotherapy, were developed without promising…
- Trial name
- NCT00367497
- Testing
- Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin
- Where
- Japan
- Volunteers
- 5 people
- Sponsor
- Keio University
B Cell Leukemia, B Cell Lymphoma
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Autologous T cells engineered to express chimeric antigen receptors (CARs) against leukemia antigens such as CD19 on B cells have shown promising results for the treatment of relapsed or refractory B-cell malignancies.
- Trial name
- NCT03166878
- Testing
- UCART019
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.